FOLR1 as a therapeutic target in platinum-resistant ovarian carcinoma:unique expression patterns across ovarian carcinoma histotypes and molecular subtypes of low-grade serous carcinoma
- Author:
Yuen Yee LEUNG
1
;
Marta LLAURADO-FERNANDEZ
;
Anna CAMERON
;
Annalyn DA-ANOY
;
Linda C. COOK
;
Joshua HOENISCH
;
Chanel GHESQUIERE
;
Stephanie GAILLARD
;
Josie SCHMID
;
Amy DAWSON
;
Madison BITTNER
;
Hannah KIM
;
Nelson K.Y. WONG
;
Gurdial DHILLION
;
Anna V. TINKER
;
Mark S. CAREY
;
Martin KÖBEL
Author Information
- Publication Type:Original Article
- From:Journal of Gynecologic Oncology 2025;36(5):e74-
- CountryRepublic of Korea
- Language:English
-
Abstract:
Objective:With the development of novel antibody-drug conjugates (ADCs), folate receptor alpha (FOLR1) is a promising therapeutic target for the treatment of platinum-resistant tuboovarian carcinomas. The main aims of this study were to assess FOLR1 protein expression in a large cohort of ovarian carcinoma histotypes. To inform future clinical trial design we identified molecular correlates of FOLR1 expression in low-grade serous carcinoma (LGSC).
Methods:One thousand five hundred forty-seven ovarian carcinoma samples from 5 different Canadian cohorts were successfully evaluated by immunohistochemistry for FOLR1 expression using the PS2+ system. Statistical analyses with clinicopathological parameters, LGSC molecular subtypes, and overall survival (OS) were performed.
Results:High FOLR1 expression was detected in 44% of high-grade serous carcinomas, and in 30% LGSC, 8% clear cell, 6% endometrioid, and 0% mucinous and/or mesonephrictype adenocarcinomas. In 160 LGSC cases, FOLR1 expression was more frequent in cases with normal MAPK pathway status (37% MAPK wild type vs. 14% canonical MAPK pathway mutations; p=0.002), low progesterone receptor (PR) expression (41%) vs. 23% (Allred score >2; p=0.02), and p16 loss (48% p16 absent vs. 26% normal; p=0.03). Canonical MAPK mutation status and PR expression remained significant on multivariable analysis. No significant associations between OS and FOLR1 expression were observed.
Conclusion:A significant proportion of LGSC express high FOLR1 levels supporting the development of clinical trials to investigate ADCs targeting FOLR1 as novel agents for treating this disease. In LGSC, high FOLR1 expression was associated with fewer MAPK pathway alterations, low PR expression, and p16 loss.
